In its second quarter earnings call, drug maker AbbVie revealed that, in the United States, Humira sales grew by $3.8 billion last quarter, up 7.7% from the prior year, with volume growth of approximately 7%.
In its second quarter earnings call, drug maker AbbVie revealed that, in the United States, Humira sales grew by $3.8 billion last quarter, up 7.7% from the prior year, with volume growth of approximately 7%.
Additionally, in the third quarter of this year, the company expects US Humira sales to grow by approximately 8%.
Furthermore, AbbVie’s spate of settlements with biosimilar developers with products referencing Humira “reinforces our confidence that we will not see direct biosimilar competition in the US until 2023,” said Rick Gonzalez, chief executive officer of AbbVie. Gonzalez also added that the company does not expect a prospective arrival of a biosimilar etanercept—2 of which are approved but unlaunched in the United States—to impact US Humira sales.
International sales of Humira, however, were down by $1.1 billion, or 31% on an operational basis, which Gonzalez said reflects “the impact of direct biosimilar competition in Europe” and other ex-US markets.
Other drivers of AbbVie’s revenue this quarter—which totaled more than $8.2 billion and exceeded expectations—were the oncology drugs ibrutinib (Imbruvica) and venetoclax (Venclexta) as well as risankizumab (Skyrizi), a treatment for plaque psoriasis.
Michael Severino, MD, executive vice president of research and development and chief scientific officer of AbbVie, added that the company expects an approval for upadacitinib shortly in the indication of rheumatoid arthritis without the convocation of an FDA advisory committee. Severino indicated that, while he cannot speak to the FDA’s position on whether JAKs as a class share similar safety concerns, such as those that led to a new warning for tofacitinib just last week, “we’ve said consistently [that] our program hasn’t demonstrated that risk.”
In looking toward the future, Gonzalez said that AbbVie’s acquisition of Allergan will give the company an opportunity to grow its non-Humira business, and to derive “significant additional earnings” when Humira faces US competition.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.